Auxly Cannabis Group

Corporate Presentation

March 2024 Auxly



Disclaimer

Legal Disclaimer

The information provided herein is not intended to provide financial, tax, legal or accounting advice. The contents hereof do not constitute an offer to sell or a solicitation of an offer to buy securities of Auxly Cannabis Group Inc. (the "**Company**") or represent an intention to induce any person to make an investment in the Company or to assist any person in the making of an investment decision. Information provided in this document is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state in the United States of America in which such offer, solicitation or sale would be unlawful. This presentation includes market share, industry and other statistical information that the Company has obtained from independent industry publications, government publications, market research reports and other published independent sources. Such publications and reports generally state that the information contained therein, has been obtained from sources believed to be reliable. Although the Company believes these publications and reports to be reliable, it has not independently verified any of the data or other statistical information contained therein, nor has it ascertained or validated the underlying economic or other assumptions relied upon by these sources. The Company has no intention and undertakes no obligation to update or revise any such information or data, whether as a result of new information, future events or otherwise, except as, and to the extent required by applicable securities laws.

Forward-looking Information

This corporate document contains "forward-looking statements" and "forward-looking information" (collectively, "**forward-looking information**") within the meaning of applicable securities legislation. Thereafter, all references should be to "forward-looking information". This corporate document may use words such as "may", "would", "could", "will", "likely", "expect", "anticipate", "believe", "intend", "plan", "forecast", "project", "estimate", "outlook", and other similar expressions to identify forward-looking information. In addition, the Company's assessment of, and targets for, future cultivation, production timelines, product launches, facility licences and amendments, average selling prices, cost of goods sold, operating expenses, gross margin on finished cannabis inventory sold and adjusted EBITDA are considered forward-looking information. Forward-looking information in this corporate document, and, accordingly, investors should not place undue reliance on any such forward-looking information. Forward-looking information intolves significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking information involves risks and uncertainties including, but not limited to, the Company's anticipated business, strategies, anticipated trends in the Company's business and anticipated market share, general business, economic and competitive uncertainties, regulatory risks including risks related to the cannabis market in the United States, Europe, Latin America and Canada, and market risks, that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information. New factors or to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those expressed or implied by the forward-looking informatio

Use of Non-IFRS Measures

This presentation refers to Adjusted EBITDA and Gross Margin on Finished Cannabis Inventory Sold because certain investors may use this information to assess the Company's performance and also determine the Company's ability to generate cash flow. This data is furnished to provide additional information and are non-IFRS measures and do not have any standardized meaning prescribed by IFRS. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS.



Vision to be a global leader in cannabis products

Mission helping consumers live happier lives by providing them with quality cannabis products that they trust and love

- Founded in 2017; headquartered in Toronto, Ontario
- Consistently ranked among the top 10 LPs in national sales since legalization
- Track record of consumer-focused innovation
- Established portfolio of popular brands
- Extensive consumer-tailored product suite
- Focused product development and genetics expansion utilizing its state-of-the-art greenhouse facility

Industry Leading Product Development



Auxly has held a leadership position in national vape sales since legalization



Since introducing its unique genetic strains to the market, Auxly has captured significant market share in the most competitive category in the industry



Industry-leading technology in pre-roll manufacturing has propelled Auxly to the forefront in the pre-roll category



Corporate Timeline A Persistent Drive for Excellence



Q4 2023¹

Secured the top 2 Vape SKU spots in Ontario



Key Strengths

Quality Cannabis Products Passionately Crafted for Everyday Happiness



State-of-the-art facilities and equipment that ensure a consistent product that meets our vigorous quality, safety and cost efficiency standards Carefully curated product suite that speaks directly to each of our targeted consumers Dedicated team that works tirelessly to meet ongoing market demand and ensure continued executional excellence



Dedicated to Canadian Consumers Leading the Market in Quality Products

Product Development	 Reputation in Canada for producing high quality, safe and effective products 	and
	 Best-in-class in-house analytical lab operated by experienced analytical scientists 	A REAL P
	 Developed proprietary testing methods to monitor and measure product quality, stability and consistency in real-time 	
Manufacturing	 Designed sophisticated quality management systems across all areas of operations 	
	 Stringent quality control across all the Company's facilities ensuring the delivery of quality products that have been thoroughly tested and inspected 	
Compliance	 History of regulatory and compliance excellence with Health Canada 	
	 Auxly has received a "Class A+" Vendor status (highest rating possible) with the Ontario Cannabis Store for inbound quality inspections due to its high compliance record 	

A Culture of Regulatory and Compliance Excellence

GREN FORIN

Our Brands

Compelling Brands Across All Major Price Points



Back Forty a simple, uncomplicated cannabis brand that already feels familiar. High potency suite of products, consumers don't need to overthink its purpose.



Kolab Project offers a refined collection of highquality cannabis products and design-focused, purposeful goods.



Foray is a versatile, modern, and inviting brand, designed for the curious. It's an accessible entry point for anybody and aims to celebrate and guide one's foray into cannabis.



Dosecann is a wellness focused brand that embraces science to unlock the therapeutic power of cannabis.



Parcel is an ultra-value brand that delivers quality cannabis at unbeatable prices, disproving the idea that less expensive equals lower quality.



A Portfolio of Winning Products


Product Categories	BACK FORTY	KOLAB PROJECT	Parcel	Foray
Dried Flower				
Pre-Roll			 Image: A start of the start of	
Vapes				 Image: A start of the start of
Edibles	 Image: A start of the start of			\checkmark
Concentrates				
Oils (bottle; capsule)				
Topical				











High-Quality, Low-Cost Cultivation Advantage

Auxly Leamington



Overview & Capabilities

- 1.1 million sq. ft. purpose-built, highly Ontario
- Customized growing environment with and humidity
- high-quality product
 - Moving Table System
 - Climate Controls

 - Automated Packaging
- ongoing R&D program to meet evolving consumer needs

automated greenhouse facility in Leamington,

precision control over lighting, temperature

State-of-the-art technology and automation throughout the facility allows for consistent

Craft-At-Scale Post-Harvest Processes


Unique genetics portfolio (~200 cultivars) with

Significant quality upgrades made in 2023 include hang drying, curing and dry trim



The Future of Pre-Roll Automation is Here

Next-Generation Pre-Roll Capabilities



Overview

- capabilities
- know-how
- ensure consistent, high-quality product
- Q4 2024¹

World's most advanced high-speed cannabis pre-roll filling and packaging

• Unrivaled operational and technical

Strain-specific primary processes to

#1 and #2 Pre-Roll SKUs nationally in

Category expansion through format innovation and portfolio expansion



Innovation and Manufacturing Excellence

Auxly Charlottetown



Overview & Capabilities

- Purpose-built, 52,000 sq. ft. processing and Cannabis 2.0 product manufacturing facility located in Charlottetown, PEI
- Specializes in research and development, innovation and advanced manufacturing
- Culture of innovation
 - First-to-market innovations across product classes
 - ~100 new SKUs developed over last two years
- Recognized as an industry leader in product quality
- Material product development and manufacturing know-how across all product classes



Driving Continued Growth

Increasing Breadth and Depth of Distribution

- Auxly has supply arrangements on the recreational side with 10 provincial and territorial boards (BC, AB, MB, ON, NL, NS, NB, PEI, NWT, YT), and one wholesaler (Open Fields - SK market).
- Auxly is present in over 91% of all stores in Canada¹
- Strategic partnerships in place with 20 retail chains (total of 768 retail stores)
- Auxly has agreements with five major medical distributors





2023 Overview





- 5th largest LP in Canada, securing 5% of the market
- Maintained leadership position in vapes, dried flower and pre-rolls, ending the year in the #3, #6 and #5 LP positions, respectively, in national market share
- Record net revenues of \$101.1 million, an increase of 7% compared to prior vear
- Gross Margin on Finished Cannabis Inventory Sold¹ of 34% and secured 40% in Q4
- Positive Adjusted EBITDA¹ of \$1.5 million
- Generated \$8.2 million in cash flow from operations (Q4 \$7.8 million)
- SG&A declined by over 17% compared to prior year
- Extended maturity date of Auxly Learnington's credit facility to December 31, 2025
- Secured the support of strategic partner Imperial Brands plc to convert \$123.4 million of its debt and interest in exchange for 19.8% equity stake in the Company



SMALL SIZE, BIG FLAUOMR Ask your budtender about the handy all-in-one vape that puts the big Back Forty flavour in the palm of your hands.

This is Auxly / Financial Performance


1) Non-IFRS financial measures not defined by and does not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers. See the cautionary statement regarding non-IFRS financial measures in MD&A. Source: Hifyre IQ, as of March 2024





Financial Performance


Net Revenue Snapshot



This is Auxly / Financial Performance

1) Cannabis 1.0 includes Dried Flower and Pre-roll sales; Cannabis 2.0 includes edible cannabis, cannabis extracts and cannabis topicals.

Financial Performance Key Profitability Metrics



This is Auxly / Financial Performance

1) Non-IFRS financial measure not defined by and does not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers. See the cautionary statement regarding non-IFRS financial measures in MD&A.



Financial Performance

Q4 2023 Key Financial Metrics

(In Millions unless otherwise indicated)

	Q4 2023	Q4 2022	% Change
Gross revenue	39.8	36.5	9%
Excise taxes	12.9	11.8	9%
Net revenue	26.9	24.7	9%
Gross margin on finished cannabis inventory sold ¹	10.8	7.4	45%
Gross margin on finished cannabis inventory sold (%) ¹	40%	30%	33%
Selling, general and administrative expenses	9.7	9.5	2%
Adjusted EBITDA ¹	2.3	(0.8)	393%
Net income/(loss)	(54.0)	(16.1)	(236%)
Net cash provided by/(used in) operating activities	7.8	5.7	36%



This is Auxly / Financial Performance

1) Non-IFRS financial measure not defined by and does not have any standardized meaning under IFRS and might not be comparable to similar financial measures disclosed by other issuers. See the cautionary statement regarding non-IFRS financial measures in MD&A.



A Market Leader Poised for Profitability and Growth

- 5th largest LP in Canada
- Experienced and committed management team
- Industry-leading cultivation and manufacturing capabilities
- Established portfolio of brands and products with broad distribution
- Deep cannabis product development and innovation knowhow
- Track-record of quality and safety









Auxly Cannabis Group 777 Richmond St W Unit 002 Toronto Ontario M6J 0C2

Investor Relations Direct Line +1.647.812.0121 Facsimile Line +1.855.669.7881 Email info@auxly.com

